In this Issue
- Psychedelic Safety Takes Centre Stage in Berkeley
- Selection Bias and Small Sample Size Hampers Compass Pathways’ Long-Term Psilocybin Data
- Placebo Outperforms LSD in MindMed’s Microdosing Study for ADHD
- atai Bets on Bitcoin
- Potential Tweak to Ukrainian Law Could Permit Psychedelic Research
- Governor of Virginia Vetoes Compass Pathways Rescheduling Bill
- Other Stories, including: Psilocybin may help phantom limb pain; psychedelic research benefits from Canadian Cancer Society Funding; British drag queen’s death sharpens focus on ketamine.
***
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓   Regular Bulletins covering key topics and trends in the psychedelics space
✓   Regular articles and deep dives across psychedelic research, policy and business
✓   Interviews with insiders
✓   Monthly interactive database and commentary on psychedelic patents
✓   Quick-take analysis of major developments
✓   A Library of primers and explainers
✓   Access to our full back catalogue
 
								 
